Skip to content
2000
Volume 10, Issue 12
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

Glycogen phosphorylase is an important therapeutic target for the potential treatment of type 2 diabetes. The importance of computation in the search for potent, selective and drug-like glycogen phosphorylase inhibitors which may eventually lead to antihyperglycemic drugs is now firmly established. Acting solo or more effectively in combination with experiment in a multidisciplinary approach to structure based drug design, current day modeling methods are an effective means of reducing the time and money spent on costly experimental procedures. Glycogen phosphorylase is an allosteric protein with five different ligand binding sites, hence offering multiple opportunities for modulation of enzyme activity. However, the binding sites have their own individual characteristics, so that different modeling approaches may be more effective for each. This review is focused on advances in the modeling and design of new inhibitors of the enzyme aimed towards providing the reader with some useful hints towards more successful computer-aided inhibitor (drug) design targeting glycogen phosphorylase.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/138955710793177359
2010-10-01
2025-12-16
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/138955710793177359
Loading

  • Article Type:
    Research Article
Keyword(s): (3D-)pharmacophore; (flavin mono-nucleotide); (flavin-adenine dinucleotide); -1,4-linked 6, 7, or 8 D-glucopyranosyl units; 2-deoxy-glucose-6-P; 3D pharmacophore model; adequate absorption, distribution, metabolism; Allosteric activators; allosteric inhibi-tors; antihyperglycemic drugs; arginine residues; Asp283 sidechain carboxylate; benzamide derivatives; benzoyl-urea derivative; caffeine; Catalytic Site; computer-aided inhibitor; CP320626; cyclodextrins; cyclooligosaccharides; D-glucose; Desmond program; Docking; electrostatic poten-tials; free energy perturbation (FEP); GlaxoSmithKline series of anthranilimide; glucose-1-phosphate; glucose-sensitive insulin release; glycerophosphate; glycogen phosphorylase; Glycogen Phosphorylase Inhibitor Design; Glycogen Storage Site; Glycogenolysis; GP BINDING SITES; GP-inhibitor; hepatic glucose production; His377; HLGPa polypeptide chain; HypoGen module; hypoglyce-mia; insulin resis-tance; Lipinski's rule of five; local similarity index; losteric protein; matched molecular pair analysis; MM-GBSA; modeling; Monod-Wyman-Changeux model; multiple protein structure; N-Acetyl-D-glucopyranosylamine; naph-thalene group; NHCON-HCO moieties; oleanic acid GPIs; PDB complex; pharmacophore; Phe285; Purines; pyri-doxal-5'-phosphate (PLP); QikProp; QM/MM; QSAR; quantum-mechanics polarised ligand docking; RMGPb inhibition; single point energy; struc-ture-based drug design; tautomeric forms of the ligands; thiazolidine-2,4-diones; triterpene class of GPIs; type 2 diabetes; Tyr613; UDP-glucose; W1807
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test